glp 1 agonist history GLP-1 Receptor Market Growth Analysis Timeline of GLP-1 discovery and

Non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH): Because of its role in lipid metabolism and energy storage, GIP modulation is explored for liver fat accumulation and metabolic liver disease

Mitchell JL, Mollan SP, Vijay V, Sinclair AJ

It has several effects that are helpful in the treatment of T2DM: it lowers glucose production in the liver, it sensitizes tissues to insulin, and it promotes weight loss

Antihyperglycemic therapies with expansions of US food and drug administration indications to reduce cardiovascular events: prescribing patterns within an academic medical center

In 1967 Steiner showed that insulin was synthesised from a precursor protein, called proinsulin

Semaglutide is a GLP-1 agonist while tirzepatide is a combination GLP-1/GIP agonist